Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury.
about
Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver InjuryUpdate on Advances in Research on Idiosyncratic Drug-Induced Liver InjuryThe Presence, Persistence and Functional Properties of Plasmodium vivax Duffy Binding Protein II Antibodies Are Influenced by HLA Class II Allelic VariantsThe Possible Mechanism of Idiosyncratic Lapatinib-Induced Liver Injury in Patients Carrying Human Leukocyte Antigen-DRB1*07:01Human leucocyte antigen-adverse drug reaction associations: from a perspective of ethnicity.Hepatotoxicity of targeted therapy for cancer.High-Accuracy HLA Type Inference from Whole-Genome Sequencing Data Using Population Reference GraphsComprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01.Effect of YH0618 soup on chemotherapy-induced toxicity in patients with cancer who have completed chemotherapy: study protocol for a randomized controlled trial.Human leukocyte antigen genetic risk factors of drug-induced liver toxicology.Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice.Drug rechallenge following drug-induced liver injury.Genome-Wide Association Studies for Idiosyncratic Drug-Induced Hepatotoxicity: Looking Back-Looking Forward to Next-Generation Innovation.The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions.Cytochrome P450 3A4 and CYP3A5-Catalyzed Bioactivation of LapatinibEffect of Genetic Diversity in Swine Leukocyte Antigen-DRA Gene on Piglet Diarrhea.Beyond BRCA: A Pilot Program to Assess and Improve Knowledge of Pharmacogenomic Testing Among Advanced Practitioners in a Breast Cancer Treatment Setting.Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes.Liver injury and glatiramer acetate, an uncommon association: case report and literature review.Drug-induced liver injury in Oncology.Characterization of Drug-Specific Signaling Between Primary Human Hepatocytes and Immune Cells.Rash in lapatinib-treated patients is not associated with human leukocyte antigen polymorphisms.Characterization of amoxicillin- and clavulanic acid-specific T cells in patients with amoxicillin-clavulanate-induced liver injury.Role of Cytochrome P450 Enzymes in the Metabolic Activation of Tyrosine Kinase Inhibitors
P2860
Q26749054-9E365073-89C9-494F-A95A-6DA027D5AC6CQ26779078-5AC7778B-E55B-49C8-9BED-8075510BD7F0Q28396379-C24E9276-169B-47B1-9BEC-909B836A2284Q28548544-407171BE-AD56-4997-9229-88F295F6B562Q30238992-41AEE19C-1EB6-4970-BB3E-96D653099C88Q30250288-E697307A-97FC-4331-9D86-84229C6CDDC7Q36177087-D854CE78-907A-421F-9DE6-20CB50E918B5Q36762374-4196851A-9055-409F-ACC8-2F703D8DC083Q37125896-11EA4DEA-1123-4CC8-8EFD-FF8148D7F00FQ38285818-CF4EAF08-8E12-4A0B-A145-8069EACA949DQ38391340-4DE9A2B1-D5F9-439B-B604-9DC63B739958Q38906878-DABA22AE-2140-4995-92F9-50745E1CB389Q39158128-30799358-A3C9-4F17-AE04-75AD7FDBDCCEQ39427540-2CB5BBAC-41C4-4CA5-94CF-A7F289CF8089Q41640449-0DFAE4D1-EF22-433E-8888-1B5C4AA3490CQ41835816-46B1D7B6-0D00-49D4-83E5-A32ABD25CD1FQ45777686-FD835E66-DF15-4CE8-B087-58AF33F77521Q46847041-D300ADC1-99EB-4D1E-B960-B4D287F72F19Q47097362-229A99DC-C424-40B1-996D-2F8A1A61F772Q50662188-5027C54D-1D83-420B-A2F9-20F8B26B8FD8Q50699986-499D308A-A27D-4EA0-9BE5-C33B829DF6D8Q53201873-B3138FFB-C3BA-41F0-A09C-613C9FA1688DQ53497512-6FD08B98-3387-4CC3-B976-0D66B52004E5Q58788266-21D48432-616F-4934-BBC0-C2B5852B6F22
P2860
Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Prospective validation of HLA- ...... apatinib-induced liver injury.
@ast
Prospective validation of HLA- ...... apatinib-induced liver injury.
@en
type
label
Prospective validation of HLA- ...... apatinib-induced liver injury.
@ast
Prospective validation of HLA- ...... apatinib-induced liver injury.
@en
prefLabel
Prospective validation of HLA- ...... apatinib-induced liver injury.
@ast
Prospective validation of HLA- ...... apatinib-induced liver injury.
@en
P2093
P356
P1476
Prospective validation of HLA- ...... apatinib-induced liver injury.
@en
P2093
Charles J Cox
Colin F Spraggs
Daniel J Schaid
Dianne M Finkelstein
Erica Rappold
Joan Curran
Laura R Parham
Lon R Cardon
Paul E Goss
Shannon K McDonnell
P304
P356
10.1200/JCO.2013.52.9867
P407
P577
2014-03-31T00:00:00Z